Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
37.19 USD | -5.15% | -5.78% | -26.49% |
05:17pm | Ionis Pharmaceuticals Says Potential Angelman Syndrome Therapy Improves Symptoms in Phase 1/2a Study | MT |
04:38pm | Stocks in motion: Walmart, Chubb, Deere... |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-26.49% | 5.72B | |
+33.17% | 49.46B | |
+1.97% | 42.58B | |
+49.11% | 42.49B | |
-4.22% | 29.09B | |
+12.10% | 26.61B | |
-23.12% | 18.64B | |
+8.48% | 13.16B | |
+30.32% | 12.55B | |
+24.17% | 12.1B |
- Stock Market
- Equities
- IONS Stock
- News Ionis Pharmaceuticals, Inc.
- Wells Fargo Adjusts Ionis Pharmaceuticals Price Target to $88 From $92, Maintains Overweight Rating